PARIS–(BUSINESS WIRE)–Regulatory News: Le Slip Français (code ISIN : FR0014018Y10 – Mnémonique : ALLSF), acteur iconique du Made in France fondé en 2011 et groupe industriel spécialisé dans la conception, la fabrication et la distribution de sous-vêtements et vêtements d’équipement, annonce aujourd’hui la signature d’un partenariat avec KYMONO, acteur majeur du textile personnalisé pour les entreprises, qui devient le distributeur exclusif de sa gamme Fier(T). Guillaume Gibault, Président-Dir
Month: September 2026
HERNDON, Va.–(BUSINESS WIRE)—- $BKSY #AI–BlackSky’s fifth Gen-3 attains first light in hours, expanding constellation capacity and decision-making speed for customers.
CHAILLÉ-SOUS-LES-ORMEAUX, France–(BUSINESS WIRE)–Regulatory News: Hoffmann Green Cement Technologies (ISIN : FR0013451044, Mnémo : ALHGR) (« Hoffmann Green Cement » ou la « Société »), acteur industriel engagé dans la décarbonation du secteur de la construction qui conçoit et commercialise des ciments innovants sans clinker, annonce la signature d’un partenariat avec Terrena, groupe coopératif agricole de premier plan dans le Grand Ouest. Basée à Ancenis (44), Terrena est l’un des principaux
CHAILLÉ-SOUS-LES-ORMEAUX, France–(BUSINESS WIRE)–Regulatory News: Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative cold produced, clinker-free cements, announces the signing of a partnership with Terrena, a leading agricultural cooperative group in western France. Based in Ancenis (44), Terrena is one of the leadin
The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).
The following transactions have been made under the program:
| Number of shares |
Average purchase price (DKK) |
Transaction value (DKK) |
|
| Accumulated, previous announcement | 1,916,299 | 941.89 | 1,804,942,913 |
| 7 September 2026 | 10,491 | 1.101.07 | 11,551,339 |
| 8 September 2026 | 10,529 | 1.093.86 | 11,517,302 |
| 9 September 2026 | 10,954 | 1.083.08 | 11,864,007 |
| 10 September 2026 | 10,043 | 1.092.87 | 10,975,653 |
| 11 September 2026 | 9,798 | 1.100.41 | 10,781,786 |
| Accumulated under the programme | 1,968,114 | 945.90 | 1,861,633,000 |
Following settlement of the transactions stated above, Jyske Bank will own a total of 1,968,114 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 3.38% of the share capital.
Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.
Yours faithfully,
Jyske Bank
Contact: Birger Krøgh Nielsen, CFO, tel. +45 25 26 92 42
Attachment
Sampo plc, stock exchange release, 14 September 2026 at 8:30 am EEST
Sampo plc’s share buybacks week 37/2026
During week 37 (7 September 2026 – 11 September 2026), Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:
| Market (MIC Code) |
Daily volume (in number of shares) and weighted average price of the purchased shares, EUR* |
Aggregated weekly volume (in number of shares) and weighted weekly average price of the purchased shares, EUR* | |||||
| 07/09/2026 | 08/09/2026 | 09/09/2026 | 10/09/2026 | 11/09/2026 | Week 37/2026, total | ||
| AQEU | Volume | 25,371 | 80,848 | 81,065 | 52,551 | 561 | 240,396 |
| Average price | 9.63 | 9.53 | 9.38 | 9.42 | 9.45 | 9.47 | |
| CEUX | Volume | 283,865 | 283,196 | 274,328 | 262,471 | 119,209 | 1,223,069 |
| Average price | 9.66 | 9.55 | 9.45 | 9.45 | 9.46 | 9.52 | |
| TQEX | Volume | 41,668 | 39,642 | 38,696 | 36,347 | 29,489 | 185,842 |
| Average price | 9.67 | 9.55 | 9.47 | 9.44 | 9.46 | 9.53 | |
| XHEL | Volume | 510,062 | 650,176 | 646,464 | 643,590 | 166,571 | 2,616,863 |
| Average price | 9.65 | 9.54 | 9.42 | 9.45 | 9.46 | 9.50 | |
| Total, all markets | Volume | 860,966 | 1,053,862 | 1,040,553 | 994,959 | 315,830 | 4,266,170 |
| Average price | 9.65 | 9.54 | 9.43 | 9.45 | 9.46 | 9.51 | |
* rounded to two decimals
On 6 May 2026, Sampo announced a share buyback programme of up to a maximum of EUR 350 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 7 May 2026, is based on the authorisation granted by Sampo’s Annual General Meeting on 22 April 2026.
After the disclosed transactions, the company owns in total 30,519,468 Sampo A shares representing 1.15 per cent of the total number of shares in Sampo plc.
Details of each transaction are included as an appendix of this announcement.
On behalf of Sampo plc,
Morgan Stanley Co. International plc
For further information, please contact:
Mirko Hurmerinta
Interim Head of Investor Relations
tel. +358 10 516 0032
Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com
Attachment
DURHAM, N.C.–(BUSINESS WIRE)–Jaggaer, führender Anbieter für KI-gestützte Beschaffungslösungen, gab heute die Übernahme von Ivoflow bekannt, einer Plattform für Spend- und Price-Intelligence im Bereich Direktmaterialien mit Sitz in Koblenz, Deutschland. Die Transaktion wurde am 11. September 2026 abgeschlossen. Die Übernahme treibt Jaggaers Strategie, die intelligenteste Beschaffungsplattform der Branche aufzubauen, voran. Für Kunden löst die Kombination eine der hartnäckigsten Herausforderun
DURHAM, N.C.–(BUSINESS WIRE)–Jaggaer, a leader in AI-powered procurement solutions, today announced it has completed its acquisition of Ivoflow, a spend & price intelligence platform for direct materials, based in Koblenz, Germany. The transaction closed on September 11, 2026. The acquisition advances Jaggaer’s strategy to build the industry’s most intelligent procurement platform. For customers, the combination will address one of procurement’s most persistent challenges: organizations h
Allschwil, Switzerland, September 14, 2026
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its partner Asahi Kasei Therapeutics Corp. started a phase 2 clinical study in Japan with the antifungal Cresemba® (isavuconazole) for pediatric patients at risk of deep mycoses.
Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We are very pleased with the start of the pediatric study for Cresemba by our partner Asahi Kasei Therapeutics Corp. Invasive fungal infections pose a critical threat for children suffering from hematologic malignancies or immunodeficiency disorders. Despite this high-risk setting, treatment options remain limited. Making Cresemba available to pediatric patients in Japan would represent a major advance in addressing this important medical need.”
The multicenter, open-label, non-controlled study is assessing the safety and pharmacokinetics of Cresemba in children at risk from deep mycoses.
Cresemba is already approved for the treatment of children in the US, Canada, Europe and China. In Japan, Cresemba is approved for the treatment of adults with severe fungal infections, but currently not for use in pediatric patients.
About Cresemba® (isavuconazole)
Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Cresemba is marketed in more than 70 countries. In Japan, orally and intravenously administered isavuconazole is approved for use in adults for the treatment of aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma), mucormycosis, and cryptococcosis (pulmonary cryptococcosis and disseminated cryptococcosis). Isavuconazole is also approved in the European Union1, the United Kingdom2, the United States (US)3 and many additional countries, including in the Asia Pacific region.4
According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between April 2025 and March 2026 amounted to USD 782 million, a 27 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.5
Deep mycoses
Deep mycoses like invasive aspergillosis (IA), invasive mucormycosis (IM) and invasive cryptococcosis are life-threatening fungal infections that spread beyond superficial sites into deep tissues, including lung, eyes, brain, bones, the bloodstream, and other sites or organs. They predominantly affect immunocompromised patients, including patients with hematologic malignancies (blood cancer), transplant patients, or patients with immunodeficiency disorders. These infections are associated with high morbidity and mortality, also in pediatric patients.6, 7, 8
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations |
|
| Phone | +41 61 606 1102 |
| media_relations@basilea.com investor_relations@basilea.com |
|
This press release can be downloaded from www.basilea.com.
References
- European Public Assessment Report (EPAR) Cresemba: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed: September 13, 2026]
- Summary of Product Characteristics (SmPC) Cresemba: https://www.medicines.org.uk/emc/search?q=cresemba [Accessed: September 13, 2026]
- Full US prescribing information: https://www.astellas.us/docs/cresemba.pdf [Accessed: September 13, 2026]
- The registration status and approved indications may vary from country to country.
- IQVIA Analytics Link, March 2026. In-market sales reported as moving annual total (MAT) in US dollar.
- J. Cadena, G. R. Thompson 3rd, T. F. Patterson. Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of North America 2021 (35), 415-434
- M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection 2015 (21), 490.e1-490.e10
- Z. D. Pana E. Roilides, A. Warris et al. Epidemiology of Invasive Fungal Disease in Children. Journal of the Pediatric Infectious Diseases Society 2017 (6), suppl. 1, S3-S11
Attachment
Dear shareholder,
Dear Madam, Dear Sir,
The board of directors invites the shareholders to attend the extraordinary general meeting to be held on Thursday 15 October 2026 at 11.00h at the company’s seat, Begijnenvest 113, 2000 Antwerp. The shareholders are welcome as of 10.00h to facilitate compliance with the admission formalities to the meeting.
Please find attached the convening notice.
All related documents are available online: General Meetings | Ackermans & van Haaren
Best regards
Ackermans & van Haaren
Attachment
